Eileen M. Boyle, MD, PhD, on Multiple Myeloma: Sustained MRD Negativity in Newly Diagnosed Disease Treated with Immunotherapy Regimens
2022 ASH Annual Meeting and Exposition
Eileen M. Boyle, MD, PhD, of the Perlmutter Cancer Center, NYU Langone Health, discusses Fc-mediated antibody effector function, inflammation resolution, and oligoclonality and their role in predicting sustained measurable residual disease negativity in patients with newly diagnosed multiple myeloma who were treated with immunotherapy regimens. For the first time, an analysis of T-cell receptors shows that oligoclonal profiles seen on treatment may influence the fitness of the immune response (Abstract 100).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
In our study, we attempted to deconvolute the microenvironment of multiple myeloma patients in order to understand what were the determinants of response. Because as you know, there's 30% of patients that will not respond or will not achieve MRD negativity upfront in myeloma. So in order to do that, we performed single-cell analysis on 20 patients, both at diagnosis and after eight cycles of treatment, to try and understand what happened to the immune composition of that environment over time.
And we were able to identify different cellular components that will determine how the patient is going to respond. And we were particularly interested in three subtypes of cells: NK cells, monocytes and T-cells. What we saw, it was that the microenvironment was function both of time and the degree of response in the disease. And so we were able to see that, upfront, NK cells were significantly higher in good responders.
These NK cells produced interferon gamma and were associated with activated monocytes that had evidence of interferon gamma response. Similarly, we noticed that T-cells that were highly diverse in these patients. But after eight cycles of treatment, these NK cells and monocytes changed in phenotype, disappeared in some cases, and the TCE repertoire became less diverse.
In patients that did not achieve MRD negativity, on the other hand, what we saw was there were some [inaudible 00:01:51] there, but they did not display that interfering gamma signature. And the monocytes that were associated with them were in this regulatory calm phase, and the T-cell repertoire was not very diverse. But after eight cycles of treatment, changes did appear, and we did notice that the monocytes attempted to display some evidence of interferon activation, suggesting there was still a chronic antigen stimulations. T-cells were more diverse, suggesting that we did have a microenvironment, after eight cycles of treatment, that could be potentially manipulated in order to improve the depth of response in these poor responders early on.
What we need to do with this data is, of course, validate it and use it in order to build better both diagnostic markers early on and potential therapeutic implications that we can use at these cells and manipulate the microenvironment to increase the depth of response in these patients.
Related Videos
The ASCO Post Staff
Kathryn R. Tringale, MD, of Memorial Sloan Kettering Cancer Center, discusses an assessment of 559 patients with primary central nervous system (CNS) lymphoma and the factors associated with consolidation therapy selection, outcomes after consolidation therapy accounting for patient factors, and patterns of disease failure. The initial treatment response was prognostic and predictive of relapse patterns (Abstract 557).
The ASCO Post Staff
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings of the ALPINE study, which showed that zanubrutinib is more efficacious and better tolerated than ibrutinib as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In this first head-to-head comparison of the two BTK inhibitors, the superior progression-free survival of zanubrutinib was observed across all major subgroups, including high-risk patients (Abstract LBA-6).
The ASCO Post Staff
Eva Hoster, PhD, of Munich University, discusses results from the European MCL Elderly Trial, which confirmed the strong efficacy of rituximab maintenance in minimal residual disease (MRD)-negative patients with mantle cell lymphoma (MCL) after induction. Omitting maintenance based on MRD-negativity is thus discouraged. Considering the short time to progression, more effective treatment strategies should be explored in MRD-positive patients to improve long-term prognosis (Abstract 544).
The ASCO Post Staff
Jia Ruan, MD, PhD, of Meyer Cancer Center, Weill Cornell Medicine, and NewYork-Presbyterian Hospital, discusses trial results demonstrating that the triple chemotherapy-free combination of acalabrutinib, lenalidomide, and rituximab is well tolerated, highly effective, and produces high rates of minimal residual disease (MRD)-negative complete response as an initial treatment for patients with mantle cell lymphoma, including those with TP53 mutations. Real-time MRD analysis may enable treatment de-escalation during maintenance to minimize toxicity, which warrants further evaluation. An expansion cohort of acalabrutinib/lenalidomide/obinutuzumab is being launched (Abstract 73).
The ASCO Post Staff
Anand P. Jillella, MD, of Georgia Cancer Center at Augusta University, discusses results from the ECOG-ACRIN EA9131 Trial, which showed that using a simplified treatment algorithm and management recommendations made by a group of specialists, resulted in a dramatic improvement in 1-year survival of patients with acute promyelocytic leukemia (Abstract 421).
